WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Shionogi wins US approval for first pill to prevent Covid following exposure

Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.

Raccontata dahealio.comfiercepharma.comendpoints.news

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo1 g fa

Shionogi wins US approval for first pill to prevent Covid following exposure

Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.

originale
healio.com1 g fa

FDA approves Xocova for COVID-19 prevention after exposure

The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to someone with the disease, according to the drug’s manufacturer, Shionogi.Xocova (ensitrelvir)…

Leggi questa versione → originale

Timeline cronologica

  1. lunedì 1 giugno 2026·healio.com

    FDA approves Xocova for COVID-19 prevention after exposure

    The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to someone with the disease, according to the drug’s…

  2. lunedì 1 giugno 2026·fiercepharma.com

    Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative

    After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a prior misfire in demonstrating its protease…

fiercepharma.com1 g fa

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a…

Leggi questa versione → originale
  • lunedì 1 giugno 2026·endpoints.news

    Shionogi wins US approval for first pill to prevent Covid following exposure

    Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.